Huberman Lab
Huberman Lab

Jun 4, 2026 · 41 min

Psychiatry shifts focus from chemical imbalances to rewiring neural circuits

Essentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams

As traditional pharmaceuticals fall short for millions, new circuit-targeted therapies offer rapid and lasting relief for treatment-resistant depression and PTSD.

3 key takeaways
  1. 1Psychiatry is transitioning to a circuit-based model that targets specific brain networks directly.
  2. 2Transcranial Magnetic Stimulation offers a non-invasive way to physically stimulate and rewire underactive neural pathways.
  3. 3Psychedelics like psilocybin and ibogaine act as powerful catalysts for rapid, therapeutic neuroplasticity.

Don't miss

Dr. Nolan Williams details the shift to Psychiatry 3.0, where neuromodulation and psychedelics physically remodel faulty brain circuits.

The brief

Modern psychiatry is undergoing a paradigm shift from chemical imbalance models to a focus on brain circuitry, ushering in an era of targeted neuromodulation to treat severe mental health conditions.

Dr. Nolan Williams explains that technologies like Transcranial Magnetic Stimulation can physically stimulate and rewire underactive brain networks to rapidly alleviate deep depression.

Alongside hardware-based stimulation, powerful compounds like MDMA, psilocybin, and ibogaine are being studied for their ability to induce rapid neuroplasticity and heal trauma.

By combining precise electrical stimulation with psychedelic-assisted therapy, clinicians aim to achieve durable, long-term remission for treatment-resistant PTSD and depression.

What was said on this episode

54 statements · 37 positive · 9 negative · 3 mixed · 5 neutral

  1. Depression is the world’s most disabling condition.

    “depression is the most disabling condition worldwide”

    Listen at 0:56

  2. Depression is the world’s most disabling condition.

    “Depression is the most disabling condition worldwide.”

    Listen at 0:56

  3. Nolan Williamson Transcranial magnetic stimulationPositive1:40

    TMS can decelerate heart rate through brain stimulation.

    “with transcranial magnetic stimulation, a form of brain stimulation, we can actually decelerate the heart rate”

    Listen at 1:40

  4. Nolan Williamson Dorsolateral prefrontal cortex–heart connectionNeutral3:54

    The heart is consistently an end organ of the dorsolateral prefrontal cortex.

    “the heart very consistently seems to be the end organ of the dorsolateral prefrontal cortex”

    Listen at 3:54

  5. Nolan Williamson Transcranial magnetic stimulationPositive4:24

    TMS is an especially promising approach for depression-related cognitive regulation.

    “TMS is really interesting, actually.”

    Listen at 4:24

  6. Nolan Williamson Transcranial magnetic stimulationPositive4:49

    TMS can externally provide cognitive functions impaired by depression.

    “I actually see TMS as a way of having kind of exogenous sorts of cognitive functions”

    Listen at 4:49

  7. Nolan Williamson Transcranial magnetic stimulationPositive5:47

    TMS restores left dorsolateral prefrontal control over the cingulate area.

    “What we see with TMS over that region is that we just exogenously do the same sort of thing. We restore the governance of the left dorsolateral over the cingulate area.”

    Listen at 5:47

  8. Nolan Williamson Transcranial magnetic stimulationPositive6:10

    Greater left dorsolateral retiming produces a stronger antidepressant effect.

    “the more of an antidepressant effect you have.”

    Listen at 6:10

  9. Nolan Williamson TMS regulation of the left dorsolateral cortex over the cingulatePositive6:10

    Greater left dorsolateral regulation of the cingulate produces stronger antidepressant effects.

    “the more of an antidepressant effect you have”

    Listen at 6:10

  10. Nolan Williamson Transcranial magnetic stimulationPositive6:12

    Repeated TMS stimulation functions similarly to brain exercise.

    “TMS is almost like exercise for the brain, right?”

    Listen at 6:12

  11. Nolan Williamson Rapid five-day TMSPositive6:38

    Some rapid-TMS patients reach near-zero depression scores by midweek.

    “By Wednesday they're like totally zeroed out on the depression scales”

    Listen at 6:38

  12. Nolan Williamson SSRIsPositive9:48

    SSRIs improve depression and several anxiety-related disorders in some patients.

    “SSRIs clearly work, you know, many, many meta analyses kind of proving that out”

    Listen at 9:48

  13. Nolan Williamson SSRIsPositive9:48

    SSRIs benefit some patients with depression and anxiety-related disorders.

    “SSRIs clearly work”

    Listen at 9:48

  14. Nolan Williamson SSRIsNegative10:14

    SSRIs do not produce therapeutic effects on the day treatment begins.

    “they don't work immediately, right? So they don't work like the same day you start taking them.”

    Listen at 10:14

  15. Nolan Williamson SSRIsNegative10:14

    SSRIs do not produce immediate effects after treatment begins.

    “they don't work immediately”

    Listen at 10:14

  16. Nolan Williamson Serotonin chemical-imbalance model of depressionNegative10:31

    Depression is not caused by an inborn serotonin deficit or chemical imbalance.

    “There's not a deficit of serotonin. You're not born with what people call a chemical imbalance.”

    Listen at 10:31

  17. Nolan Williamson Transcranial magnetic stimulationPositive12:12

    TMS can work without introducing serotonin into the brain.

    “TMS works and there's no serotonin coming in or out of the brain.”

    Listen at 12:12

  18. Nolan Williamson Psilocybin and ketaminePositive12:57

    Psilocybin and ketamine are associated with circuit-level brain changes after the drugs leave the body.

    “there are a lot of groups that are actually doing neuroimaging before and after, and they're able to see circuit level changes for something like psilocybin or ketamine long after the drug is gone”

    Listen at 12:57

  19. Nolan Williamson Psilocybin and ketamineNeutral13:01

    Psilocybin and ketamine are associated with lasting circuit-level brain changes after clearance.

    “they're able to see circuit level changes for something like psilocybin or ketamine long after the drug is gone”

    Listen at 13:01

  20. Nolan Williamson Psychiatric illnessesPositive14:16

    People with psychiatric illnesses can recover.

    “People can get better.”

    Listen at 14:16

  21. Nolan Williamson Psychiatric illnessPositive14:16

    Psychiatric illness can be recoverable and people can improve.

    “people can get better”

    Listen at 14:16

  22. Nolan Williamson TMS and psychedelic treatmentsPositive14:22

    TMS and psychedelic treatments can restore normal mood within five days or less.

    “people are actually in normal levels of mood for sustained periods of time within five days, within five or less days.”

    Listen at 14:22

  23. Nolan Williamson Psychedelic treatmentPositive14:32

    Psychedelic treatment can move people out of depressive states within days.

    “within a few days, we can get people out of these states”

    Listen at 14:32

  24. Nolan Williamson MDMA and psilocybinPositive16:57

    MDMA and psilocybin appear to produce relatively long-lasting therapeutic effects for trauma-related phenomena.

    “some new, like mdma, some that have been around for thousands of years, like psilocybin, seem to have a therapeutic effect that seems to be pretty long lasting for these phenomenon.”

    Listen at 16:57

  25. Nolan Williamson MDMAPositive18:25

    One to several MDMA sessions appear to reduce PTSD symptoms.

    “MDMA appears to, in one to a few MDMA sessions, have an anti PTSD effect”

    Listen at 18:25

  26. Nolan Williamson MDMA-assisted treatment for PTSDPositive19:13

    About two-thirds of participants had clinically significant PTSD improvement after MDMA.

    “It's about 2/3 of people had a clinically significant change in their ptsd.”

    Listen at 19:13

  27. Nolan Williamson MDMA-assisted treatment for PTSDPositive19:25

    MDMA-related PTSD improvements lasted for years in some participants.

    “it seemed to last for kind of in the years range for some people”

    Listen at 19:25

  28. A single ketamine infusion produces antidepressant effects lasting about one and a half weeks on average.

    “with ketamine, which only on average lasts about a week and a half for a single infusion”

    Listen at 19:32

  29. A single ketamine infusion provides depression relief for about one and a half weeks on average.

    “ketamine, which only on average lasts about a week and a half for a single infusion”

    Listen at 19:32

  30. Nolan Williamson Psilocybin for depression and MDMA for PTSDPositive19:53

    Psilocybin for depression and MDMA for PTSD appear more promising than ketamine to Williams.

    “the psilocybin story for depression and the MDMA story for PTSD seem more interesting to me”

    Listen at 19:53

  31. Nolan Williamson PsilocybinPositive20:09

    Open-label psilocybin studies report improvement in roughly half to two-thirds of participants.

    “it's closer to half to 2/3 of people end up getting better depending upon their level of treatment.”

    Listen at 20:09

  32. Nolan Williamson Psilocybin for depressionPositive20:14

    Blinded psilocybin depression trials improved roughly one-third of participants.

    “In the blinded trials, it was more like a third or so of people”

    Listen at 20:14

  33. Psychedelics produce an overall decrease in brain activity.

    “what they found is the opposite, right? There's kind of a, an overall decrease in the level of activity in the brain with psychedelics.”

    Listen at 22:01

  34. Psychedelics increase global brain connectivity.

    “the connectivity kind of global connectivity kind of increases”

    Listen at 22:32

  35. Nolan Williamson Psilocybin and TMS connectivity changesPositive23:32

    Psilocybin and TMS produce a shared connectivity change linked to antidepressant effects.

    “you see that same connectivity change occur post psilocybin, suggesting there's a convergent mechanism”

    Listen at 23:32

  36. Nolan Williamson Psilocybin and TMSPositive23:38

    Psilocybin and TMS appear to share a convergent antidepressant mechanism.

    “suggesting there's a convergent mechanism.”

    Listen at 23:38

  37. Ibogaine may be unusually potent but carries substantial cardiac risk.

    “ibogaine is kind of both seemingly the most potent and most, seemingly to me at least most powerful psychedelic, but the one that has the most risk too, because it has a cardiac effect”

    Listen at 26:10

  38. Nolan Williamson ibogainePositive26:27

    ECG screening can substantially reduce ibogaine-related cardiac risk.

    “you can screen people out that have risk off of their electrocardiogram and reduce the risk quite a bit”

    Listen at 26:27

  39. Nolan Williamson Psychedelic drugsPositive28:18

    Psychedelic drugs could represent a major psychiatric breakthrough.

    “these sorts of drugs are a huge breakthrough in psychiatry”

    Listen at 28:18

  40. Nolan Williamson Psychedelic drugs as a psychiatric breakthroughNeutral28:47

    Evidence is currently insufficient to establish psychedelics as a psychiatric breakthrough.

    “we don't know if that statement is true”

    Listen at 28:47

  41. Nolan Williamson Psychedelic-assisted therapyPositive28:56

    If validated, psychedelic-assisted cognitive reexamination will likely be considered a psychiatric breakthrough.

    “if it is true, then it's very likely that this will be seen as a breakthrough”

    Listen at 28:56

  42. Psychedelics such as ibogaine should not be used recreationally.

    “these drugs can't be recreational drugs. They really shouldn't be recreational drugs.”

    Listen at 29:14

  43. Nolan Williamson Psychedelic substancesNegative29:17

    Psychedelic substances should not be used recreationally.

    “They really shouldn't be recreational drugs.”

    Listen at 29:17

  44. Nolan Williamson Psychedelic substancesNegative30:01

    Psychedelic substances require strict medical supervision outside research settings.

    “the idea that some of these substances would go outside of very strict medical supervision is kind of preposterous”

    Listen at 30:01

  45. Ayahuasca has been investigated as an antidepressant treatment.

    “that substance has been explored as an antidepressant agent”

    Listen at 32:43

  46. Nolan Williamson AyahuascaPositive33:11

    Ayahuasca appears safe based on cited research.

    “And so it appears to be safe.”

    Listen at 33:11

  47. Nolan Williamson AyahuascaPositive33:11

    Ayahuasca appears to be safe based on available observations.

    “it appears to be safe.”

    Listen at 33:11

  48. Nolan Williamson AyahuascaPositive33:54

    Ayahuasca exposure was associated with lower prisoner recidivism than control treatment.

    “the recidivism rate or the return to prison rate in the ayahuasca exposed individuals was statistically significantly lower than the recidivism rate in the control group”

    Listen at 33:54

  49. Nolan Williamson Psychedelic administration in prisonsNegative34:20

    Prisons should not simply administer psychedelics to inmates.

    “I am also in no way saying that we should just be giving psychedelics to folks in prison”

    Listen at 34:20

  50. Nolan Williamson Accelerated TMS protocolPositive38:22

    The protocol delivers seven and a half months of standard TMS dosing in five days.

    “We're going to have seven and a half months worth in five days using space learning theory”

    Listen at 38:22

  51. SAINT can produce remission within one to five days.

    “within one to five days”

    Listen at 38:42

  52. SAINT produces full mood remission in roughly 60% to 90% of cases.

    “somewhere between 60 and 90% of the time they will go into full on remission”

    Listen at 38:48

  53. Nolan Williamson Accelerated TMS protocolPositive39:04

    Some accelerated-TMS patients have maintained remission for one to four years.

    “for some people, we've had four years of remission, a year of remission”

    Listen at 39:04

  54. Patients report no side effects and feeling normal after completing SAINT.

    “people, when they kind of exit out of that, they end up, they end up saying they don't have any side effects from it and they feel back to normal.”

    Listen at 39:55

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Weekly email

State of the Pod, every Monday

The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

Listen to the full episode and explore every guest, topic, and moment on PodLume.